Literature DB >> 11530804

Proliferative capacity of single isolated CD34+ hematopoietic stem/progenitor cells in paroxysmal nocturnal hemoglobinuria.

B Han1, Y Wu, Z Lu, Z Zhang.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) results from somatic mutations of the X-linked PIG-A (phosphatidylinositol glycan-class A) gene, which occurs on a hematopoietic stem cell level, leading to a proportion of blood cells being deficient in all glycosylphosphatidylinositol (GPI)-anchored surface proteins. Although these GPI-deficient cells can explain many of the clinical symptoms of PNH, the pathogenesis of PNH is still somewhat obscure and many questions remain. To assess the hematopoietic defect involved in PNH, CD34+ CD59+ (normal phenotype hematopoietic stem/progenitor) and CD34+ CD59- (PNH phenotype) cells from PNH patients (n = 16) and CD34+ CD59+ cells from healthy volunteers (n = 10) were sorted as single cells into 96-well flat-bottom culture plates containing culture medium supplemented with stem cell factor, interleukin (IL)-3, erythropoietin, granulocyte-macrophage-colony-stimulating factor (GM-CSF), G-CSF, IL-6, thrombopoietin, and Flt-3 ligand. We found that the single PNH CD34+ CD59- cells had a growth advantage over the single CD34+ CD59+ cells to some extent, but they both had impaired growth abilities compared with CD34+ cells from healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11530804     DOI: 10.1007/BF02982548

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  47 in total

Review 1.  The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated.

Authors:  N S Young
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

Review 2.  Structure and function of the leukocyte adhesion molecules CD11/CD18.

Authors:  M A Arnaout
Journal:  Blood       Date:  1990-03-01       Impact factor: 22.113

3.  Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow.

Authors:  C I Civin; M L Banquerigo; L C Strauss; M R Loken
Journal:  Exp Hematol       Date:  1987-01       Impact factor: 3.084

Review 4.  CD34: structure, biology, and clinical utility.

Authors:  D S Krause; M J Fackler; C I Civin; W S May
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

5.  Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria.

Authors:  R A Brodsky; M S Vala; J P Barber; M E Medof; R J Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

6.  Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.

Authors:  T Wiedmer; S E Hall; T L Ortel; W H Kane; W F Rosse; P J Sims
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

7.  Circulating primitive stem cells in paroxysmal nocturnal hemoglobinuria (PNH) are predominantly normal in phenotype but granulocyte colony-stimulating factor treatment mobilizes mainly PNH stem cells.

Authors:  R J Johnson; A C Rawstron; S Richards; G J Morgan; D R Norfolk; S O Hillmen
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

8.  Peripheral blood harvest of unaffected CD34+ CD38- hematopoietic precursors in paroxysmal nocturnal hemoglobinuria.

Authors:  G M Prince; M Nguyen; H M Lazarus; R A Brodsky; L W Terstappen; M E Medof
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

9.  Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link.

Authors:  A Griscelli-Bennaceur; E Gluckman; M L Scrobohaci; P Jonveaux; T Vu; A Bazarbachi; E D Carosella; F Sigaux; G Socié
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

10.  Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry.

Authors:  D R Sutherland; A Keating; R Nayar; S Anania; A K Stewart
Journal:  Exp Hematol       Date:  1994-09       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.